DiaMedica Therapeutics (DMAC) Common Equity (2017 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Common Equity of $47.2 million for Q1 2026, up 39.11% year-over-year from $34.0 million in Q1 2025, and down 15.82% quarter-over-quarter from $56.1 million in Q4 2025.
DiaMedica Therapeutics (DMAC) Common Equity (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics' Common Equity history runs 10 years deep, the most recent figure standing at $47.2 million for Q1 2026.
- In Q1 2026, Common Equity rose 39.11% year-over-year to $47.2 million; the TTM figure through Mar 2026 stood at $47.2 million (up 39.11% YoY), while the FY2025 annual figure was $56.1 million, up 37.8% from the prior year.
- Common Equity for Q1 2026 stood at $47.2 million, down from $56.1 million in the prior quarter.
- The five-year high for Common Equity was $59.7 million in Q2 2023, with the low at $27.0 million in Q1 2023.
- The 5-year median for Common Equity is $46.3 million (2024), against an average of $43.7 million.
- The sharpest annual moves came in 2022 and 2025: Common Equity soared 85.62% in 2022, then slumped 49.13% in 2025.
- DiaMedica Therapeutics' Common Equity stood at $31.8 million in 2022, then jumped by 60.42% to $51.1 million in 2023, then fell by 20.25% to $40.7 million in 2024, then soared by 37.8% to $56.1 million in 2025, then fell by 15.82% to $47.2 million in 2026.
- Business Quant data shows DMAC's Common Equity at $47.2 million in Q1 2026, $56.1 million in Q4 2025, and $51.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | 38.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.34 Mn |
| Mar 31, 2026 | 47.24 Mn |
| Dec 31, 2025 | 56.11 Mn |
| Sep 30, 2025 | 51.60 Mn |
| Jun 30, 2025 | 27.17 Mn |
| Mar 31, 2025 | 33.95 Mn |
| Dec 31, 2024 | 40.72 Mn |
| Sep 30, 2024 | 47.96 Mn |
| Jun 30, 2024 | 53.42 Mn |
| Mar 31, 2024 | 46.35 Mn |
| Dec 31, 2023 | 51.06 Mn |
| Sep 30, 2023 | 55.63 Mn |
| Jun 30, 2023 | 59.74 Mn |
| Mar 31, 2023 | 27.02 Mn |
| Dec 31, 2022 | 31.83 Mn |
| Sep 30, 2022 | 35.08 Mn |
| Jun 30, 2022 | 37.72 Mn |
| Mar 31, 2022 | 40.77 Mn |
| Dec 31, 2021 | 44.02 Mn |
| Sep 30, 2021 | 47.04 Mn |